Pulmonary Function Decline After Neoadjuvant Chemoimmunotherapy in Lung Cancer (DGT 2026) - Sep 9, 2026 - Abstract #A-244; Pres time: Sep 11, 2026; 11:40 AM - 11:47 AM; Location: Watford Hall; "Neoadjuvant CI is associated with a significant decline in DLCO and KCO and an increase in airway resistance.Further studies are needed to better understand the underlying pathophysiological mechanisms and to refine patient selection criteria for neoadjuvant CI."
Clinical • IO biomarker • Lung Cancer • Oncology • Solid Tumor • PD-L1
|
|
Ö. Okumus1; H. Kaman1; T. Stork1; E.L. Buchmeier2; C. Groß-Ophoff-Müller2; T.P.H. Köster3; W. Windisch4; S. Collaud1
|